Current Approaches to Germline Cancer Genetic Testing

Literature Cited

1. 1. 

   Collins FS, Green ED, Guttmacher AE, Guyer MS, Institute USNHGR. 2003. A vision for the future of genomics research. Nature 422:835–47
   [Google Scholar]
2. 2. 

   Pon JR, Marra MA. 2015. Driver and passenger mutations in cancer. Annu. Rev. Pathol. 10:25–50
   [Google Scholar]
3. 3. 

   Grady WM, Carethers JM. 2008. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 135:1079–99
   [Google Scholar]
4. 4. 

   Carethers JM, Jung BH. 2015. Genetics and genetic biomarkers in sporadic colorectal cancer. Gastroenterology 149:1177–90
   [Google Scholar]
5. 5. 

   Stoffel EM, Boland CR. 2015. Genetics and genetic testing in hereditary colorectal cancer. Gastroentero-logy 149:1191–203
   [Google Scholar]
6. 6. 

   Robinson DR, Wu YM, Lonigro RJ et al. 2017. Integrative clinical genomics of metastatic cancer. Nature 548:297–303
   [Google Scholar]
7. 7. 

   Mody RJ, Wu YM, Lonigro RJ et al. 2015. Integrative clinical sequencing in the management of refractory or relapsed cancer in youth. JAMA 314:913–25
   [Google Scholar]
8. 8. 

   Zhang J, Walsh MF, Wu G et al. 2015. Germline mutations in predisposition genes in pediatric cancer. N. Engl. J. Med. 373:2336–46
   [Google Scholar]
9. 9. 

   Mandelker D, Zhang L, Kemel Y et al. 2017. Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA versus guideline-based germline testing. JAMA 318:825–35
   [Google Scholar]
10. 10. 

    Yurgelun MB, Kulke MH, Fuchs CS et al. 2017. Cancer susceptibility gene mutations in individuals with colorectal cancer. J. Clin. Oncol. 35:1086–95
    [Google Scholar]
11. 11. 

    Brand R, Borazanci E, Speare V et al. 2018. Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma. Cancer 124:3520–27
    [Google Scholar]
12. 12. 

    Yurgelun MB, Chittenden AB, Morales-Oyarvide V et al. 2019. Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Genet. Med. 21:213–23
    [Google Scholar]
13. 13. 

    Pritchard CC, Mateo J, Walsh MF et al. 2016. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N. Engl. J. Med. 375:443–53
    [Google Scholar]
14. 14. 

    Walsh T, Casadei S, Lee MK et al. 2011. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. PNAS 108:18032–37
    [Google Scholar]
15. 15. 

    Norquist BM, Harrell MI, Brady MF et al. 2016. Inherited mutations in women with ovarian carcinoma. JAMA Oncol 2:482–90
    [Google Scholar]
16. 16. 

    Easton DF, Pharoah PD, Antoniou AC et al. 2015. Gene-panel sequencing and the prediction of breast-cancer risk. N. Engl. J. Med. 372:2243–57
    [Google Scholar]
17. 17. 

    Manchanda R, Legood R, Burnell M et al. 2015. Cost-effectiveness of population screening for BRCA mutations in Ashkenazi Jewish women compared with family history-based testing. J. Natl. Cancer Inst. 107:380
    [Google Scholar]
18. 18. 

    Kuchenbaecker KB, Hopper JL, Barnes DR et al. 2017. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317:2402–16
    [Google Scholar]
19. 19. 

    Berry DA, Iversen ES Jr., Gudbjartsson DF et al. 2002. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J. Clin. Oncol. 20:2701–12
    [Google Scholar]
20. 20. 

    Grant RC, Holter S, Borgida A et al. 2018. Comparison of practice guidelines, BRCAPRO, and genetic counselor estimates to identify germline BRCA1 and BRCA2 mutations in pancreatic cancer. J. Genet. Couns. 27:988–95
    [Google Scholar]
21. 21. 

    National Comprehensive Cancer Network (NCCN) 2019. Genetic/familial high risk assessment: breast and ovarian. NCCN Clinical Practice Guidelines in Oncology. Version 3.2019. http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf
    [Google Scholar]
22. 22. 

    American Society of Breast Surgeons 2019. Consensus guideline on genetic testing for hereditary breast cancer. https://breastsurgeons.org/docs/statements/Consensus-Guideline-on-Genetic-Testing-for-Hereditary-Breast-Cancer.pdf
23. 23. 

    Levy-Lahad E, Lahad A, King MC 2015. Precision medicine meets public health: population screening for BRCA1 and BRCA2. J. Natl. Cancer Inst 107:420
    [Google Scholar]
24. 24. 

    Moyer VA, US Preventive Services Task Force. 2014. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 160:271–81
    [Google Scholar]
25. 25. 

    Fong PC, Boss DS, Yap TA et al. 2009. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361:123–34
    [Google Scholar]
26. 26. 

    Moore K, Colombo N, Scambia G et al. 2018. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 379:2495–505
    [Google Scholar]
27. 27. 

    Golan T, Hammel P, Reni M et al. 2019. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N. Engl. J. Med. 381:317–27
    [Google Scholar]
28. 28. 

    Mateo J, Carreira S, Sandhu S et al. 2015. DNA-repair defects and olaparib in metastatic prostate cancer. N. Engl. J. Med. 373:1697–708
    [Google Scholar]
29. 29. 

    Domchek SM, Friebel TM, Singer CF et al. 2010. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304:967–75
    [Google Scholar]
30. 30. 

    Giri VN, Knudsen KE, Kelly WK et al. 2018. Role of genetic testing for inherited prostate cancer risk: Philadelphia Prostate Cancer Consensus Conference 2017. J. Clin. Oncol. 36:414–24
    [Google Scholar]
31. 31. 

    Stoffel EM, McKernin SE, Brand R et al. 2019. Evaluating susceptibility to pancreatic cancer: ASCO provisional clinical opinion. J. Clin. Oncol. 37:153–64
    [Google Scholar]
32. 32. 

    Hampel H, Frankel WL, Martin E et al. 2005. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N. Engl. J. Med. 352:1851–60
    [Google Scholar]
33. 33. 

    Haraldsdottir S, Rafnar T, Frankel WL et al. 2017. Comprehensive population-wide analysis of Lynch syndrome in Iceland reveals founder mutations in MSH6 and PMS2. Nat. Commun. 8:14755
    [Google Scholar]
34. 34. 

    Syngal S, Brand RE, Church JM et al. 2015. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am. J. Gastroenterol. 110:223–62
    [Google Scholar]
35. 35. 

    Carethers JM. 2017. Microsatellite instability pathway and EMAST in colorectal cancer. Curr. Colorectal Cancer Rep. 13:73–80
    [Google Scholar]
36. 36. 

    Carethers JM. 2016. Hereditary, sporadic and metastatic colorectal cancers are commonly driven by specific spectrums of defective DNA mismatch repair components. Trans. Am. Clin. Climatol. Assoc. 127:81–97
    [Google Scholar]
37. 37. 

    Kastrinos F, Uno H, Ukaegbu C et al. 2017. Development and validation of the PREMM5 model for comprehensive risk assessment of Lynch syndrome. J. Clin. Oncol. 35:2165–72
    [Google Scholar]
38. 38. 

    Dinh TA, Rosner BI, Atwood JC et al. 2011. Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev. Res. 4:9–22
    [Google Scholar]
39. 39. 

    Evaluation of Genomic Applications in Practice and Prevention Working Group 2009. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet. Med. 11:35–41
    [Google Scholar]
40. 40. 

    Latham A, Srinivasan P, Kemel Y et al. 2019. Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer. J. Clin. Oncol. 37:286–95
    [Google Scholar]
41. 41. 

    Le DT, Uram JN, Wang H et al. 2015. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372:2509–20
    [Google Scholar]
42. 42. 

    Schmeler KM, Lynch HT, Chen LM et al. 2006. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N. Engl. J. Med. 354:261–69
    [Google Scholar]
43. 43. 

    Lu KH, Wood ME, Daniels M et al. 2014. American Society of Clinical Oncology expert statement: collection and use of a cancer family history for oncology providers. J. Clin. Oncol. 32:833–40
    [Google Scholar]
44. 44. 

    Stoffel EM, Koeppe E, Everett J et al. 2017. Germline genetic features of young individuals with co-lorectal cancer. Gastroenterology 154:897–905
    [Google Scholar]
45. 45. 

    Pearlman R, Frankel WL, Swanson B et al. 2017. Prevalence and spectrum of germline cancer susceptibility gene mutations among patients with early-onset colorectal cancer. JAMA Oncol 3:464–71
    [Google Scholar]
46. 46. 

    National Comprehensive Cancer Network (NCCN) 2018. Genetic/familial high-risk assessment: colorectal. NCCN Clinical Practice Guidelines in Oncology. Version 1.2018. http://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf
47. 47. 

    Ladabaum U, Wang G, Terdiman J et al. 2011. Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann. Intern. Med. 155:69–79
    [Google Scholar]
48. 48. 

    Khoury MJ, Feero WG, Chambers DA et al. 2018. A collaborative translational research framework for evaluating and implementing the appropriate use of human genome sequencing to improve health. PLOS Med 15:e1002631
    [Google Scholar]
49. 49. 

    Hughes KS. 2017. Genetic testing: What problem are we trying to solve. ? J. Clin. Oncol. 35:3789–91
    [Google Scholar]
50. 50. 

    Haddow JE, Palomaki GE. 2003. ACCE: a model process for evaluating data on emerging genetic tests. Human Genome Epidemiology: A Scientific Foundation for Using Genetic Information to Improve Health and Prevent Disease M Khoury, J Little, W Burke 217–33 New York: Oxford Univ. Press
    [Google Scholar]
51. 51. 

    Richards S, Aziz N, Bale S et al. 2015. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17:405–24
    [Google Scholar]
52. 52. 

    Offit K. 2016. The future of clinical cancer genomics. Semin. Oncol. 43:615–22
    [Google Scholar]
53. 53. 

    Gill J, Obley AJ, Prasad V 2018. Direct-to-consumer genetic testing: the implications of the US FDA's first marketing authorization for BRCA mutation testing. JAMA 319:2377–78
    [Google Scholar]
54. 54. 

    Kurian AW, Hare EE, Mills MA et al. 2014. Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J. Clin. Oncol. 32:2001–9
    [Google Scholar]
55. 55. 

    Yurgelun MB, Allen B, Kaldate RR et al. 2015. Identification of a variety of mutations in cancer predisposition genes in patients with suspected Lynch syndrome. Gastroenterology 149:604–13
    [Google Scholar]
56. 56. 

    Carethers JM, Stoffel EM. 2015. Lynch syndrome and Lynch syndrome mimics: the growing complex landscape of hereditary colon cancer. World J. Gastroenterol. 21:9253–61
    [Google Scholar]
57. 57. 

    Katona BW, Yurgelun MB, Garber JE et al. 2018. A counseling framework for moderate-penetrance colorectal cancer susceptibility genes. Genet. Med. 20:1324–27
    [Google Scholar]
58. 58. 

    Domchek SM, Bradbury A, Garber JE et al. 2013. Multiplex genetic testing for cancer susceptibility: out on the high wire without a net. ? J. Clin. Oncol. 31:1267–70
    [Google Scholar]
59. 59. 

    Robson ME, Bradbury AR, Arun B et al. 2015. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J. Clin. Oncol. 33:3660–67
    [Google Scholar]
60. 60. 

    Hampel H, Bennett RL, Buchanan A et al. 2015. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. Genet. Med. 17:70–87
    [Google Scholar]
61. 61. 

    Kurian AW, Li Y, Hamilton AS et al. 2017. Gaps in incorporating germline genetic testing into treatment decision-making for early-stage breast cancer. J. Clin. Oncol. 35:2232–39
    [Google Scholar]
62. 62. 

    Fox D, Spencer E, Torkamani A 2018. Returning results to family members: professional duties in genomics research in the United States. J. Leg. Med. 38:201–19
    [Google Scholar]
63. 63. 

    Childers CP, Childers KK, Maggard-Gibbons M, Macinko J 2017. National estimates of genetic testing in women with a history of breast or ovarian cancer. J. Clin. Oncol. 35:3800–6
    [Google Scholar]
64. 64. 

    Roberts JS, Gornick MC, Carere DA et al. 2017. Direct-to-consumer genetic testing: user motivations, decision making, and perceived utility of results. Public Health Genom 20:36–45
    [Google Scholar]
65. 65. 

    Plichta JK, Sebastian ML, Smith LA et al. 2019. Germline genetic testing: what the breast surgeon needs to know. Ann. Surg. Oncol. 26:2184–90
    [Google Scholar]
66. 66. 

    Khoury MJ, Iademarco MF, Riley WT 2016. Precision public health for the era of precision medicine. Am. J. Prev. Med. 50:398–401
    [Google Scholar]